We published that statins sensitize to venetoclax-mediated killing in CLL, AML, and B-cell lymphoma through a mechanism involving p53-independent upregulation of the p53 upregulated modulator of apoptosis (PUMA; ref. 25). This evidence concerns the gene TP53 and acute myeloid leukemia.